1094TiP A randomized, controlled, open-label, phase II study of cemiplimab as a single agent and in combination with RP1 in patients with advanced cutaneous squamous cell carcinoma [CERPASS]
A.M. Haydon
◽
M. Alamgeer
◽
D. Brungs
◽
F. Collichio
◽
N.I. Khushalani
◽
...